Published in Nat Med on June 01, 2009
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest (2013) 2.08
The contribution of bone to whole-organism physiology. Nature (2012) 2.03
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol (2013) 1.70
Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J Exp Med (2012) 1.28
A RANKL-PKCβ-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts. Genes Dev (2013) 1.15
Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion. Proc Natl Acad Sci U S A (2010) 1.13
Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2. PLoS One (2010) 1.00
Hypomagnesaemia associated with long-term use of proton pump inhibitors. Gastroenterol Rep (Oxf) (2014) 0.96
Osteopetrosis and its relevance for the discovery of new functions associated with the skeleton. Int J Endocrinol (2015) 0.94
Regulation of lysosome biogenesis and functions in osteoclasts. Cell Cycle (2013) 0.87
Optic nerve compression and retinal degeneration in Tcirg1 mutant mice lacking the vacuolar-type H-ATPase a3 subunit. PLoS One (2010) 0.86
The role of the gastrointestinal tract in calcium homeostasis and bone remodeling. Osteoporos Int (2013) 0.85
Stress fractures in elderly patients. Int Orthop (2012) 0.85
Calcium gluconate supplementation is effective to balance calcium homeostasis in patients with gastrectomy. Osteoporos Int (2014) 0.84
Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength. PLoS One (2011) 0.84
Stomaching calcium for bone health. Nat Med (2009) 0.84
High fluoride and low calcium levels in drinking water is associated with low bone mass, reduced bone quality and fragility fractures in sheep. Osteoporos Int (2014) 0.79
Bone seems susceptible to range of drugs. Nat Med (2009) 0.79
Pharmacological estrogen administration causes a FSH-independent osteo-anabolic effect requiring ER alpha in osteoblasts. PLoS One (2012) 0.79
Gastrin-deficient mice have disturbed hematopoiesis in response to iron deficiency. Endocrinology (2011) 0.79
A close look at acid reflux drugs points to possible risks. Nat Med (2009) 0.77
A high-calcium diet failed to rescue an osteopenia phenotype in claudin-18 knockout mice. Physiol Rep (2014) 0.77
[Vitamin D metabolism of the bone]. Orthopade (2015) 0.76
Hypochlorhydria-induced calcium malabsorption does not affect fracture healing but increases post-traumatic bone loss in the intact skeleton. J Orthop Res (2016) 0.76
Contribution of immunomodulators to gastroesophageal reflux disease and its complications: stromal cells, interleukin 4, and adiponectin. Ann N Y Acad Sci (2016) 0.75
Osteopetrorickets due to Snx10 deficiency in mice results from both failed osteoclast activity and loss of gastric acid-dependent calcium absorption. PLoS Genet (2015) 0.75
Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and Facilitates Runx2-mediated Osteoblastogenesis. EBioMedicine (2015) 0.75
Analysis of Patients with Helicobacter pylori Infection and the Subsequent Risk of Developing Osteoporosis after Eradication Therapy: A Nationwide Population-Based Cohort Study. PLoS One (2016) 0.75
Vacuolar-type H+-ATPase-mediated proton transport in the rat parietal cell. Pflugers Arch (2011) 0.75
Serologically Determined Gastric Mucosal Condition Is a Predictive Factor for Osteoporosis in Japanese Men. Dig Dis Sci (2015) 0.75
[Calcium and vitamin D in osteology]. Z Rheumatol (2015) 0.75
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 14.89
Epidemiology and outcomes of osteoporotic fractures. Lancet (2002) 13.09
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Genetic regulation of osteoclast development and function. Nat Rev Genet (2003) 7.94
The vacuolar (H+)-ATPases--nature's most versatile proton pumps. Nat Rev Mol Cell Biol (2002) 5.19
Control of osteoblast function and regulation of bone mass. Nature (2003) 5.06
Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell (2001) 4.36
Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet (2000) 3.12
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med (2005) 2.98
Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet (1999) 2.46
Calcium absorption and achlorhydria. N Engl J Med (1985) 2.36
Genetics, pathogenesis and complications of osteopetrosis. Bone (2007) 2.25
Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med (2003) 2.17
Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet (2000) 2.04
Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J (2005) 1.96
ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature (2006) 1.91
Bcl-2 lies downstream of parathyroid hormone-related peptide in a signaling pathway that regulates chondrocyte maturation during skeletal development. J Cell Biol (1997) 1.87
Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet (2005) 1.63
The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone (2000) 1.55
Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res (2003) 1.55
Mice with a targeted disruption of the AE2 Cl-/HCO3- exchanger are achlorhydric. J Biol Chem (2004) 1.50
Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract (2007) 1.47
Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med (1985) 1.39
Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology (1997) 1.37
Who is using chronic acid suppression therapy and why? Am J Gastroenterol (2003) 1.34
Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transplant (2003) 1.34
Autosomal recessive osteopetrosis: diagnosis, management, and outcome. Arch Dis Child (2000) 1.32
The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet (2001) 1.29
Osteopetrorickets. The paradox of plenty. Pathophysiology and treatment. Clin Orthop Relat Res (1993) 1.27
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest (2002) 1.24
Hypertrophic gastropathy resembling Ménétrier's disease in transgenic mice overexpressing transforming growth factor alpha in the stomach. J Clin Invest (1992) 1.20
Tissue microarrays. Biotechniques (2004) 1.20
The high mobility group transcription factor Sox8 is a negative regulator of osteoblast differentiation. J Cell Biol (2005) 1.19
Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. Am J Pathol (2003) 1.09
Paget's disease of bone: histologic analysis of 754 patients. J Bone Miner Res (2009) 1.05
Rickets and osteopetrosis: the osteosclerotic (oc) mouse. Clin Orthop Relat Res (1985) 1.05
Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit. Biochem Biophys Res Commun (1996) 1.03
Osteopetrorickets. J Trop Pediatr (2004) 1.03
Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. J Bone Miner Res (2006) 1.01
Calcitonin deficiency in mice progressively results in high bone turnover. J Bone Miner Res (2006) 0.99
PTH and PTHrP effects on the skeleton. Rev Endocr Metab Disord (2000) 0.99
Comparison of prevalence of chronic atrophic gastritis in Japan, China, Tanzania, and the Dominican Republic. Ann Epidemiol (2005) 0.92
Osteosclerosis, a recessive skeletal mutation on chromosome 19 in the mouse. J Hered (1985) 0.92
Hypochlorhydria: a factor in nutrition. Annu Rev Nutr (1989) 0.91
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res (2002) 5.99
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 5.64
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell (2010) 5.08
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol (2004) 3.49
Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet (2003) 3.44
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
Virtual autopsy as an alternative to traditional medical autopsy in the intensive care unit: a prospective cohort study. Ann Intern Med (2012) 3.29
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med (2002) 3.03
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Clin Invest (2011) 2.60
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol (2004) 2.32
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Biologically inactive leptin and early-onset extreme obesity. N Engl J Med (2015) 2.26
Genetics, pathogenesis and complications of osteopetrosis. Bone (2007) 2.25
Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med (2003) 2.17
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat (2005) 2.10
A six-gene signature predicting breast cancer lung metastasis. Cancer Res (2008) 2.09
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer (2006) 2.04
Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer (2002) 2.04
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet (2007) 2.04
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Lysosomal pathology and osteopetrosis upon loss of H+-driven lysosomal Cl- accumulation. Science (2010) 2.03
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet (2012) 2.02
Rhinosinusitis: Establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg (2004) 2.01
Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell (2004) 2.00
Novel mutations in Indian patients with autosomal recessive infantile malignant osteopetrosis. Indian J Med Res (2010) 1.98
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene (2002) 1.97
Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J (2005) 1.96
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
A single-center experience in 20 patients with infantile malignant osteopetrosis. Am J Hematol (2009) 1.91
RAG-dependent primary immunodeficiencies. Hum Mutat (2006) 1.91
Mutations in PYCR1 cause cutis laxa with progeroid features. Nat Genet (2009) 1.89
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood (2009) 1.89
Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res (2010) 1.88
Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica (2005) 1.83
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab (2010) 1.79
Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol (2004) 1.77
WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. J Exp Med (2007) 1.77
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res (2007) 1.76
The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One (2012) 1.76
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol (2004) 1.75
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med (2008) 1.71
Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol (2013) 1.70